Clinical Trial Update: Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing low-dose bevacizumab and pemetrexed against a control regimen in metastatic HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Pemetrexed (Alimta) (pemetrexed)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN